Legumain在人眼眶横纹肌肉瘤中的表达及其与肿瘤侵袭性的关系
摘要
目的
1检测人眼眶横纹肌肉瘤(rhabdomyosarcoma,RMS)组织中legumain的表达,观察legumain的表达与RMS生物学行为之间的关系。并对横纹肌肉瘤患者的多个临床指标与患者预后进行多因素分析,对影响生存率的独立因素进行分析讨论。
2检测经不同浓度的转化生长因子β(transforming growth factorβ,TGF-β)刺激之后人胚胎型RMS细胞系RD细胞中legumain及α-平滑肌肌动蛋白(α-smooth muscle actin,α-SMA)表达的变化,探讨legumain在RD细胞中的作用,为肿瘤的治疗提供新的思路和策略。
方法
1应用免疫组化SP法检测56例人眼眶RMS患者手术标本中legumain的表达,并引入年龄、性别、组织学类型、肿瘤大小、是否累及眼睑等因素进行统计学分析,观察各因素与患者预后的关系。
2首先利用细胞免疫荧光法检测1egumain在RD细胞中的表达情况,并使用不同浓度的TGF-β对RD细胞进行刺激,通过RT-PCR以及Western-blot技术检测刺激前后legumain及α-SMA在RD细胞中表达的变化。
结果
1 legumain在56例RMS组织中有25例高表达,并且其表达高低、肿瘤大小、组织学类型、是否累及眼睑等因素是影响横纹肌肉瘤患者生存率的独立临床因素。
2通过细胞免疫荧光法检测到RD细胞中存在legumain的表达,并且legumain及α-SMA的表达在2.5ng／ml的TGF-β刺激后较正常对照组明显升高,而5ng／ml刺激后RD细胞中legumain及α-SMA的表达较正常对照组明显降低。
结论
1 legumain在RMS组织中具有较高的表达,检测人眼眶RMS组织中legumain的表达有望成为判断肿瘤恶性程度以及患者预后的生物学指标,并为以后临床治疗眼眶RMS提供实验基础。
2 Legumian低表达、肿瘤≦5cm、胚胎型RMS、肿瘤未累及眼睑的病人均具有较高生存率。而患者的年龄、性别因素与患者的预后无关。
3低浓度的TGF-p刺激提高了RD细胞中legumain及α-SMA的表达,而高浓度的TGF-β刺激降低了RD细胞中legumain及α-SMA的表达,由于低浓度的TGF-β可以促进RD细胞的生长,而高浓度的TGF-β可以通过某种途径抑制RD细胞的生长,因此,legumain可能通过某种途径参与了TGF-β调控RD细胞生长的环节,从而增加了肿瘤细胞的侵袭性。
Objective
1 To investigate the expression of legumain in human orbital rhabdomyosarcoma as well as their relation with biological behaviour of human orbital rhabdomyosarcoma. And analyse the independent clinical factors that affected the survival of patients with rhabdomyosarcoma.
2 To detect the expression of legumain and a-SMA in RD cell line stimulated with different concentration of TGF-βand invest the effect of legumain in RD cell line in order to provide new stratagies in tumor treatment.
Methods
1 The expression of legumain was evaluated in the 56 operative samples of human orbital rhabdomyosarcoma by immunohistochemistry and study the relationship between legumain expression and clinical factors including age, sex, histological type, tumor size, eyelid involved or not and prognosis of patients.
2 The expression of legumain was detected by immunofluorescence. The expression of legumain and a-SMA in RD cell line stimulated with different concentration of TGF-βwere detected through RT-PCR and Western-blot.
Results
1 High expression of legumain were detected in 25 samples of human orbital rhabdomyosarcoma. The expression levels of legumain and the independent clinical factors such as histological type, tumor size, eyelid involved could affect survival of patients with rhbadomyosarcoma.
2 The expression level of legumain and a-SMA in RD cell line stimulated with 2.5ng/ml of TGF-βwere higher than that of normal control group while stimulated with 5ng/ml the expression level of legumain and a-SMA in RD cell line were lower than that of normal control group.
Conlusion
1 The expression of legumain in human orbital rhabdomyosarcoma were high and detecting the expression of legumain may be become biological index for malignancy and prognosis factors of human orbital rhabdomyosarcoma.
2 Patients with low level of legumain exprssion, tumor size≦5cm, embryonal RMS, without eyelid involved had better prognosis.
3 The expression level of legumain and a-SMA in RD cell line stimulated with 2.5ng/ml of TGF-βincreased while down regulated in RD cell line stimulated with 5ng/ml of TGF-β. Different concentration of TGF-βhave different effects on prolifaration of RD cell line, legumain may play important roles in the process of RD proliferation and increase the invasion activity of RD cells.
1检测人眼眶横纹肌肉瘤(rhabdomyosarcoma,RMS)组织中legumain的表达,观察legumain的表达与RMS生物学行为之间的关系。并对横纹肌肉瘤患者的多个临床指标与患者预后进行多因素分析,对影响生存率的独立因素进行分析讨论。
2检测经不同浓度的转化生长因子β(transforming growth factorβ,TGF-β)刺激之后人胚胎型RMS细胞系RD细胞中legumain及α-平滑肌肌动蛋白(α-smooth muscle actin,α-SMA)表达的变化,探讨legumain在RD细胞中的作用,为肿瘤的治疗提供新的思路和策略。
方法
1应用免疫组化SP法检测56例人眼眶RMS患者手术标本中legumain的表达,并引入年龄、性别、组织学类型、肿瘤大小、是否累及眼睑等因素进行统计学分析,观察各因素与患者预后的关系。
2首先利用细胞免疫荧光法检测1egumain在RD细胞中的表达情况,并使用不同浓度的TGF-β对RD细胞进行刺激,通过RT-PCR以及Western-blot技术检测刺激前后legumain及α-SMA在RD细胞中表达的变化。
结果
1 legumain在56例RMS组织中有25例高表达,并且其表达高低、肿瘤大小、组织学类型、是否累及眼睑等因素是影响横纹肌肉瘤患者生存率的独立临床因素。
2通过细胞免疫荧光法检测到RD细胞中存在legumain的表达,并且legumain及α-SMA的表达在2.5ng／ml的TGF-β刺激后较正常对照组明显升高,而5ng／ml刺激后RD细胞中legumain及α-SMA的表达较正常对照组明显降低。
结论
1 legumain在RMS组织中具有较高的表达,检测人眼眶RMS组织中legumain的表达有望成为判断肿瘤恶性程度以及患者预后的生物学指标,并为以后临床治疗眼眶RMS提供实验基础。
2 Legumian低表达、肿瘤≦5cm、胚胎型RMS、肿瘤未累及眼睑的病人均具有较高生存率。而患者的年龄、性别因素与患者的预后无关。
3低浓度的TGF-p刺激提高了RD细胞中legumain及α-SMA的表达,而高浓度的TGF-β刺激降低了RD细胞中legumain及α-SMA的表达,由于低浓度的TGF-β可以促进RD细胞的生长,而高浓度的TGF-β可以通过某种途径抑制RD细胞的生长,因此,legumain可能通过某种途径参与了TGF-β调控RD细胞生长的环节,从而增加了肿瘤细胞的侵袭性。
Objective
1 To investigate the expression of legumain in human orbital rhabdomyosarcoma as well as their relation with biological behaviour of human orbital rhabdomyosarcoma. And analyse the independent clinical factors that affected the survival of patients with rhabdomyosarcoma.
2 To detect the expression of legumain and a-SMA in RD cell line stimulated with different concentration of TGF-βand invest the effect of legumain in RD cell line in order to provide new stratagies in tumor treatment.
Methods
1 The expression of legumain was evaluated in the 56 operative samples of human orbital rhabdomyosarcoma by immunohistochemistry and study the relationship between legumain expression and clinical factors including age, sex, histological type, tumor size, eyelid involved or not and prognosis of patients.
2 The expression of legumain was detected by immunofluorescence. The expression of legumain and a-SMA in RD cell line stimulated with different concentration of TGF-βwere detected through RT-PCR and Western-blot.
Results
1 High expression of legumain were detected in 25 samples of human orbital rhabdomyosarcoma. The expression levels of legumain and the independent clinical factors such as histological type, tumor size, eyelid involved could affect survival of patients with rhbadomyosarcoma.
2 The expression level of legumain and a-SMA in RD cell line stimulated with 2.5ng/ml of TGF-βwere higher than that of normal control group while stimulated with 5ng/ml the expression level of legumain and a-SMA in RD cell line were lower than that of normal control group.
Conlusion
1 The expression of legumain in human orbital rhabdomyosarcoma were high and detecting the expression of legumain may be become biological index for malignancy and prognosis factors of human orbital rhabdomyosarcoma.
2 Patients with low level of legumain exprssion, tumor size≦5cm, embryonal RMS, without eyelid involved had better prognosis.
3 The expression level of legumain and a-SMA in RD cell line stimulated with 2.5ng/ml of TGF-βincreased while down regulated in RD cell line stimulated with 5ng/ml of TGF-β. Different concentration of TGF-βhave different effects on prolifaration of RD cell line, legumain may play important roles in the process of RD proliferation and increase the invasion activity of RD cells.
引文
[1]Jerry A S, Carol L S. Rhabdomyosarcoma:Review for the Ophthalmologist. Survey of Ophthalmology,2003,48 (1):39-57
[2]Jerry A S, Carol L S, Richard S. Survey of 1264 patientswith orbital tumors and simulating lesions. Ophthalmology,2004,111 (5):997-1008
[3]何彦津,宋国祥,丁莹.3476例眼眶占位性病变的组织病理学分类.中华眼科杂志.2002,38(7)：396-398
[4]刘复生.中国肿瘤病理学分类(下).北京：科学技术文献出版社,2001：5
[5]Newton WA Jr, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification- an Intergroup Rhabdomyosarcoma Study. Cancer 1995; 76:1073-85.
[6]Coffin C. The new international rhabdomyosarcoma classification, its progenitors and considerations beyond morphology. Adv Anat Pathol 1997;4:1-16.
[7]Loh EWJ, Scrable HJ, Livanos E, et al. Human chromosome 11 contains two different growth supresor genes for embryonal rhabdomyosarcoma. Proc Natl Acad Sci USA1992;89:1755-9.
[8]Bridge JA, Liu J, Weibolt V, et al. Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization:an Intergroup Rhabdomyosarcoma Study. Genes Chromosome Cancer 2000;27:337-44.
[9]Barr FG. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol 1997;19:483-91.
[10]Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001;20:5736-46.
[11]Anderson J, Gordon A, Pritchard-Jones K, et al. Genes, chromosomes and rhabdomyosarcoma. Genes Chromosome Cancer 1999;26:275-85.
[12]Lohk J,Lehtl K,Westermarck J,etal. Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbo112-myristatel3-acetate[J].Eur J Biolchem,1996,239:239.
[13]Nawrocki B,Polette M,March Met al.Expression of matrix metalloproteinases and their inhibitors in human bonchoput monary carcinoma:quantificative and morphological analyses[J].Int J Cancer,1997,72:556.
[14]Kawano N,Osawa H, Takaaki L,et al.Expression of gelatinase A,tissue inhibitor of metalloproteinase-2, matrily in and trypsin (ogen) in lung neoplasms[J].Human Pathol,1997,28:613.
[15]Kitagawa Y,Kunimi K,Uchibayashi T,et al.Expression of mRNA for MT1,2,3 matrix metalloproteinase in human renal cell carcinoma [J]. J Uro 1,1999,162 (3PT):905-909.
[16]Liano E,Pendas AM,Freije JP,et al.Identification and characterization of human MTS-MMP,a new membrane bound activaor of progelatinase overexpression in brain tumor[J].Cancer Res,1999,59(11):2570-2576.
[17]Fang J, Shing Y, Yan L, et al. Matrix metalloproteinase-2 is required for switch to the angiogenic phenotype in a tumor model [J]. Proc Matl Acad Sci Usa,2000,97 (8):3884-3889.
[18]Weidner N,Folkman J,Pozza F,et al.Tumor angiogenesis:a new significant and independent prognostic indicator in early stage breast carcinoma[J]. Nat Cancer Inst,1992,84(24):1875-87.
[19]Chen JM, Fortunato M, Stevens RA et al (2001) Activation of progelatinase A by mammalian legumain, a recently discovered cysteine proteinase. Biol Chem 382(5):777-783
[20]Liu C, Sun C, Huang H et al (2003) Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res 63(11):2957-2964
[21]Murthy RV, Arbman G, Gao J et al (2005) Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res 11(6):2293-2299
[22]Kroger N, Milde-Langosch K, Riethdorf S et al (2006) Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res 12(1):159-168
[23]Crisi GM, Marconi SA, Makari-Judson G et al (2005) Expression of c-kit in adenoid cystic carcinoma of the breast. Am J Clin Pathol 124(5):733-739
[24]Muehaneta-Kubara EC, el Nahas AM, Myofibroblast phenotypes expression in Experimental renal scarring[J].Nephrol Dial Transplant,1997:12(5):904-910
[25]Noel, A, Munant, C, Nusgens, B, Lapiere, C.M. and Foidart, J.M. Different mechanisms of extracellular matrix remodeling by fibroblasts in response to human mammary neoplastic cells [J].Invasion Metastasis1993:13:72-81.
[26]Nakayama H, Enzan H, Miyazaki E, Toi M, Alpha smooth muscle actin positive Stromal cells in gastric carcinoma[J].Clin Pathol 2002:55:741-744
[27]王立峰,王瑞芬,郝兆星.胃癌中肿瘤相关纤维母细胞蛋白表达改变及意义[J].世界华人消化杂志2007.7,15(20)：2263-2267
[28]Massague J, Chen YC. Controlling TGF-β signaling.Genes Dev.2000; 14:627-644
[29]王华,杨光华,步宏等.转化生长因子β及其受体在横纹肌肉瘤的表达.临床与实验病理学杂志.2002；18：61-64.
[30]Wang Hua, Yang GunagHua, Bu Hong et al.Systematic analysis of the TGF-beta/smad signalling pathway in the rhabdomyosarcoma cell line RD. International journal of experimental phathology.2003;84(3):115-125.
[31]NCI. Cancer incidence and survival among children and adolescents:United States SEER Program 1975-1995. National Cancer Institute.
[32]Jerry A S, Carol L S. Rhabdomyosarcoma:Review for the Ophthalmologist. Survey of Ophthalmology,2003,48 (1):39-57
[33]Jerry A S, Carol L S, Richard S. Survey of 1264 patientswith orbital tumors and simulating lesions. Ophthalmology,2004,111 (5):997-1008
[34]刘复生.中国肿瘤病理学分类(下).北京：科学技术文献出版社,2001：5
[35]Shields CL, Shields JA, Honavar SG, Demirci H:Clinical spectrum of primary ophthalmic rhabdomyosarcoma. Ophthalmology,2001,108:2284-2292
[36]Barnes L.Surgical pathology of the head and neek.In:Tumors and Tumor-like lesions of the sotf tissue. NewYbrk, NY:Marcel Decker,1985:725-880
[37]Crist W, Gehan EA, Ragab AH, et al.The third Intergroup Rhabdomyosarcoma Study. J Clin oncol,1995,13(3):610-630
[38]Koscielniak E, Jurgens H, Winkler K, et al.Treatment of sot ftissue sarcoma in Children and adolescence.A report of the German Copoerative Sotf Tissue Sarcoma Study. Cance r,1992,70(10):2557-2567
[39]Newton WA Jr, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification-an Intergroup Rhabdomyosarcoma Study. Cancer 1995; 76:1073-85.
[40]Loh EWJ, Scrable HJ, Livanos E, et al. Human chromosome 11 contains two different growth supresor genes for embryonal rhabdomyosarcoma. Proc Natl Acad Sci USA 1992;89:1755-9.
[41]Bridge JA, Liu J, Weibolt V, et al. Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization:an Intergroup Rhabdomyosarcoma Study. Genes Chromosome Cancer 2000;27:337-44.
[42]Barr FG. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol 1997;19:483-91.
[43]Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001;20:5736-46.
[44]Anderson J, Gordon A, Pritchard-Jones K, et al. Genes, chromosomes and rhabdomyosarcoma. Genes Chromosome Cancer 1999;26:275-85.
[45]Barrett AJ, Rawlings ND, O'Brien EA The MEROPS database as a protease information system. J Struct Bio 2001:1134(2-3):95-102
[46]Kroger N, Milde-Langosch K, Riethdorf S et al.Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res 2006:12(1):159-168
[47]Crisi GM, Marconi SA, Makari-Judson G et al.Expression of c-kit in adenoid cystic carcinoma of the breast.Am J Clin Pathol 2005:124(5):733-739
[48]Chen JM, Fortunato M, Stevens RA et al) Activation of progelatinase A by mammalian legumain, a recently discovered cysteine proteinase. Biol Chem 2001:382(5):777-783
[49]Liu C, Sun C, Huang H et al.Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res.2003:63(11):2957-2964
[50]Parham DM. Pathologiec classification of rhabdomyosarcomas and correlation With molecular studies.Mod Pathol,2001,14(5):506-514
[51]EL-Badry OM, Minniti C, Kohn EC, et al. Insulin-like growth factor Ⅱ acts as an antocrine growth and motility factor in hmuna rhabdomyosarcoma tumors. Cell Groth Diff.1990; 1:325-331.
[52]Schweigerer L, Neufeld G, Mergia A, et al.Basic fibroblast growth factor In human Rhabdomyosarcoma cells:implications for the proliferation and neovasecularization of myoblast-derived tumors. Proc Natl Aead Sci USA,1987; 84:842-846.
[53]De Giovanni C, Landuzzi L. Frabetti F, et al.Antisense epidermal growth factor receptor transfection impairs the proliferative ability of humna rhabdomyosarcoma cells.Cancer Res.1996:56:3898-3901.
[54]Wang Hua, Yang GunagHua, Bu Hong et al.Systematic analysis of the TGF-beta/smad signalling pathway in the rhabdomyosarcoma cell line RD. International journal of experimental phathology.2003;84(3):115-125.
[55]Massague J, Chen YC. Controlling TGF-β signaling.Genes Dev.2000; 14:627-644
[56]Jeffrey LW, Liliana A, Juan Carcamo, et al. TGF-β signals through a heteromeric protein kinase receptor complex.Cell.1992;71:1003-1014.
[57]Heldin CH, Miyazon Kohei, Ten Dijke P. TGF-β signalling from cell membrane to nucleus through smad protein.Nature.1997;390:465-471
[58]Robert AB, Anzano MA, Wakefield LM, et al.Type beta transforming growth factor:a bifunctional regulator of cellular groth. Proc Natl Acad Sci USA.1985; 82:119-123.
[59]Roberts AB, Anzano MA, Lamb LC, et al. New class of transforming growth factors potentiated by epidermal gorwth factor:isolation from non-neoplastic tissues. Proc. Natl. Acad.Sci.USA.1981;78(9):5339-5343.
[60]Wong SF and Lai LC. The role of TGF beta in human cancers. Pathology 2001; 33:85-92.
[61]Hu XiaoTang, Zhang XiaoHong, et al.Differential effects of transforming growth factor on cell cycle regulatory molecules in human myeloid leukemia cells.Oncogene.2001:20:6840-6850.
[62]Kamaraju AK and Roberts AB.Roel of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-beta-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo.J Biol Chem.2005;14, 280(2):1024-1036.
[63]de Lujan Alvarez M, Ronco MT, Ochoa JE, et al.Interferon alpha-induced apoptosis on rat preneoplastic liver is mediated by hepatocytic transforming gorwth factor beta(1), Hepatology2004:40(2):394-402.
[64]Danforth DN Jr. All trans-retinoic acid acts synergistically wih hydroxytamoxifen and transforming gorwth factor beta to stimulate apoptosis in MCF-7 breast cancer cells. J Endocrinol.2004:183(2):395-404.
[65]Nawshad A, LaGamba D, and Hay ED.Transforming growth factor beta (TGF-β) signaling in palatal growth, apoptosis and epithelial Mesenchymal transformation (EMT). Arch Oral Biol.2004:49(9):675-689.
[66]Blobe GC, SchiemannWP, Lodish HF. Role of transforming growth factor β in human disease. New Eng J Med.2000:342:1350-1358.
[67]Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type Ⅱ TGF-beta receptor in colon cancer cells with micro-satellite instability. Science. 1995;268:1336-1338.
[68]Gorsch SM,Memoli VA,Stukel TA,Gold LI,Arrick BA.Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer.Cancer Res 1992;52:6949-6952
[69]Akhurst RJ.TGF-beta antagonists:why suppress a tumor suppressor? J Clin Invest 2002;109:1533-1536
[70]Tian F, Da Costa Byfield S,Parks WT,et al;Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines.Cancer Res2002;63:8284-8292
[71]Siegel PM,Shu W,Cardiff RD,Muller WJ,Massague J.Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis.Proc Natl Acad Sci USA 2003;100:8430-8435.
[72]Albo D,Berger DH,Tuszynski GP.The effect of thombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.J Surg Res 1998;76:86-90
[73]Farina AR,Coppa A, Tiberio A,et al.Transforming growth factor-beta 1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity.Int J Cancer 1998;75:721-730.
[74]Ohuchida K,Mizumoto K, Murakami M. et al.Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res 2004;64:3215-3222
[75]De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003;200:429-447
[76]Micke P,Ostman A.Tumor-stroma interaction:cancer-associated fibroblasts as novel targets in anti-cancer therapy?Lung Cancer 2004;45 Suppl 2:S163-175
[77]Thiery JP, Chopin D.Epithelial cell plasticity in development and tumor progression.Cancer Metastasis Rev 1999;18:31-42
[78]Zavadil J, Bottinger EP.TGF-beta and epithelial-to-mesenchymal transitions.Oncogene 2005;24:5764-5774
[79]Xu Z,Shen MX,Ma DZ et al. TGF-beta 1 promoted epithelial- to-mesenchymal transformation and cell adhesion contribute to TGF-beta enhanced cell migration in SMMC-7721 cells. Cell Res 2003;13:343-350
[80]Han G, Lu SL, Li AG,et al.Distinct mechanisms of TGF-beta 1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis.J Clin Invest 2005;115:1714-1723
[81]Peinado H,Quintanilla M,Cano A.Transforming growth factor beta-1 induces snail trancription factor in epithelial cell lines:mechanisms for epithelial mesenchymal transitions.J Biol Chem 2003;278:21113-21123
[82]Hasegawa Y,Takanashi S, Kanehira Y,et al.Transforming growth factor-beta 1 level correlates with angiogenesis,tumor progression,and prognosis in patients with nonsmsll cell lung carcinoma.Cancer 2001;91:964-971
[83]Tuxhorn JA, McAlhany SJ, Yang F,et al. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model.Cancer Res 2002;62:6021-6025
[84]Druker BJ, Mamon HJ, Roberts TM. Oncogene, growth factors, and signal transduction. New Engl J Med.1989:321:1383-1391.
[1]NCI. Cancer incidence and survival among children and adolescents:United States SEER Program 1975-1995. National Cancer Institute.
[2]Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-Ⅳ: results for patients with nonmetastatic disease. J ClinOncol,2001,19:3091-102.
[3]Andrea S, Jayant R. Rhabdomyosarcoma India J Pediatr,2004,71(4):331-337.
[4]Weiss SW, Goldblum JR. Rhabdomyosarcoma. In:Weiss SW, Goldblum JR. eds. Enzinger andWeiss's Soft Tissue Tumors. St. Louis,CV Mosby Co. Edition 4,2001, 785-835.
[5]NishiM, Hstae Y. Ep idemiology if malignment neop lasms in soft tissue during childhood j Exp Clin Cancer Res,2004,123 (3):437-440.
[6]Meyer WH, Spunt SL. Soft tissue sarcomas of childhood. Cancer Treat Rev 2004;30:269-80.
[7]Pappo AS, Shapiro DN, Crist WM, Maurer HM. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 1995;13:2123-39.
[8]Ruymann FB, Maddux HR, Ragab A, et al. Congenital anomalies associated with rhabdomyosarcoma:an autopsy study of 115 cases:a report from the Intergroup Rhabdomyosarcoma Study Committee. Med Pediatr Oncol 1988;16:33-9.
[9]Li FP, Fraumeni JR, Mulvihill JT, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988;48:5358-62.
[10]Birch JM, Hartley AL, Blair V, et al. Cancer in the families of children with soft tissue sarcoma. Cancer 1990; 66:2239-48.
[11]Bargonetti J, Manfredi JJ. Multiple roles of tumor suppressor p53. Curr Opin Oncol 2002;14:86-91.
[12]Newton WA Jr, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification- an Intergroup Rhabdomyosarcoma Study. Cancer 1995; 76:1073-85.
[13]Coffin C. The new international rhabdomyosarcoma classification, its progenitors and considerations beyond morphology. Adv Anat Pathol 1997;4:1-16.
[14]Loh EWJ, Scrable HJ, Livanos E, et al. Human chromosome 11 contains two different growth supresor genes for embryonal rhabdomyosarcoma. Proc Natl Acad Sci USA 1992;89:1755-9.
[15]Bridge JA, Liu J, Weibolt V, et al. Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization:an Intergroup Rhabdomyosarcoma Study. Genes Chromosome Cancer 2000;27:337-44.
[16]Barr FG. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol 1997;19:483-91.
[17]Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001;20:5736-46.
[18]Anderson J, Gordon A, Pritchard-Jones K, et al. Genes, chromosomes and rhabdomyosarcoma. Genes Chromosome Cancer 1999;26:275-85.
[19]Jerry A S, Carol L S. Rhabdomyosarcoma:Review for the Ophthalmologist. Survey of Ophthalmology,2003,48 (1):39-57
[20]Jerry A S, Carol L S, Richard S. Survey of 1264 patientswith orbital tumors and simulating lesions. Ophthalmology,2004,111 (5):997-1008
[21]何彦津,宋国祥,丁莹.3476例眼眶占位性病变的组织病理学分类.中华眼 科杂志.2002,38(7)：396-398
[22]刘复生.中国肿瘤病理学分类(下).北京：科学技术文献出版社,2001：5
[23]Shields CL, Shields JA, Honavar SG, Demirci H:Clinical spectrum of p rimary ophthalmic rhabdomyosarcoma. Ophthalmology,2001,108:2284-2292
[24]Herzog, C E, Stewart, JM, Blakely, M L. Pediatric soft tissue sarcomas. Surg Oncol Clin N Am,2003,12:419-420
[25]常彬,李锋,陆天才.横纹肌肉瘤分子遗传学研究进展.临床与实验病理学杂志,2003,19(1)：82-84
[26]Shields JA, Shields CL.Rhabdomyosarcoma review for the ophthalmologist Surv ophthalmol,2003; 48 (1):39-55
[27]Lanzkowsky P.Rhabdomyosarcoma and Other Soft tissue Sarcomas Manual of Pediatric Hematology and Oncology 3re eds. New York Academic Press, 2000:527-553
[28]Raney RB, Anderson JR, Kollath J. Late effects of therapy in 94 patients with localized rhabdomyosarcoma study(IRS-Ⅲ),1984-1991.Med pediatr Oncol, 2000;64(6):413-420
[29]Yip CC,Kersten RC,McCulley TJ,Ballard ET,Kulwin DR. Osteogenic sarcoma after orbital radiation rhabdomyosarcoma. Ophthalmology,2003;110(10):1196-1199
[30]Donaldson SS, Meza J, BrenemanJC, Crist WM, Laurie F, Qualman SJ, Wharam M. Result from the IRS-IV randomized trial of hyperfraction radiotherapy in children with rhabdomyosarcoma-a report from IRSG. Int J Pediat Oncol Biol Phys,2001; 51(3):718-728
[31]Suzanne L. Wolden, Leonard H, Wexler, Dennis H, Kraus, Michael P. Laquaglia, Eric Lis, Paul A. meyears intensify-modulated radiotherapy for head-and neck rhabdomyosarcoma Eur Cancer,2005;61(5):1432-1438
[32]Buwalda J, Schouwenburg PF, Blank LE, Merks JH, Copper MP, Strackee SD,Voute PA, Caron PA, Caron HN.A norel local treatlment strategy for advanced stage head and neck rhabdomyosarcoma in children.results of the AMORE protocol Eur J Cancer,2003;39(11):1594-1602
[33]Hartmann JT, Datel S.Recent developments in salvagechemotherapy for patients with metastatic soft tissue sarcoma. Drugs,2005;62(2):167-178
[34]Casanova M, Ferrari A, BisognoG.Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas:pilot study for the upcoming European Rhabdomyosarcoma Protocol Cancer,2004;101(7):1664-1671
[35]Pappo AS, Lyden E, Breneman J. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma:an intergroup rhabdomyosarcoma study.J Clin Oncol, 2001;19(1):213-219
[36]Sandler E, Lyden E, Ruymann F. Efficacyofifosfamide and doxorubicin given as a phase Ⅱ window in children with newly diagnosed metastatic rhabdomyosarcoma:a report from the Intergroup Rhabdomyosarcoma Study Group. Med pediatr Oncol,2001;37(5):442-448
[37]Breitfeld PP, Lyden E, Raney RB, Teot LA, Wharam M,Lobe T, Crist WM, Maurer HM, Donaldson SS, Ruymann FB. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic hhabdomyosarcoma when administered with irradiation and combination chemotherapy:a report from the Intergroup Rhabdomyosarcoma Study Group. J Peiatr Hematol Oncol,2001; 23(4):225-233
[38], Goto T, Kosaku H, Kobayashi H, Hozumi T, Kondo T. Soft tissue sarcoma:post-operative chemotherapy Gan To Kagaku Ryoho,2004;31 (9):1324-1330
[39]Stevens M, Ray A, Bouvet N, Ellershaw C, Sanchezde Toledo J, Oberlin O. SIOP MMT95 Intensified (6 drug)versus standard (IVA)chemotherapy for high risk nonmetastatic rhabdomyosarcoma(RMS).J Clin Oncol,2004;22(4):8515
[40]Raney RB, Anderson JR, Barr FG. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decade of life:A select review of Intergroup Rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study. J Peiatr Hematol Oncol,2001;23(4):215-220
[41]Weigel BJ, Breitfeld PP, Hawkins D, Crist WM, Baker KS.Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Peiatr Hematol Oncol,2001;23(5):272-276
[42]Veldwijk MR, Berlinghoff S, Hengge UR, Zeller WJ,Wenz F,Fruehauf S. Suicide gene therapy of sarcoma cell lines using recombinant adeno-associated virus vectors. Cancer Gene Ther,2004; 11(8):577-584
[43]Bortoluzzi S, Bisognin A,Tomualdi C, Danieli GA. Novel genes,possibly relevant for molecular diagnosis or therapy of human rhabdomyosarcoma,a detected by genomic expression profiling Gene,2005;348(3):65-71
[44]Tanzarella S, Lionello I, Valentinis B. Rhabdomyosarcoma potential target of MAGE-specific immunotherapieas.Cancer Immuno Immunother,2004; 230 (2):315-318
[2]Jerry A S, Carol L S, Richard S. Survey of 1264 patientswith orbital tumors and simulating lesions. Ophthalmology,2004,111 (5):997-1008
[3]何彦津,宋国祥,丁莹.3476例眼眶占位性病变的组织病理学分类.中华眼科杂志.2002,38(7)：396-398
[4]刘复生.中国肿瘤病理学分类(下).北京：科学技术文献出版社,2001：5
[5]Newton WA Jr, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification- an Intergroup Rhabdomyosarcoma Study. Cancer 1995; 76:1073-85.
[6]Coffin C. The new international rhabdomyosarcoma classification, its progenitors and considerations beyond morphology. Adv Anat Pathol 1997;4:1-16.
[7]Loh EWJ, Scrable HJ, Livanos E, et al. Human chromosome 11 contains two different growth supresor genes for embryonal rhabdomyosarcoma. Proc Natl Acad Sci USA1992;89:1755-9.
[8]Bridge JA, Liu J, Weibolt V, et al. Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization:an Intergroup Rhabdomyosarcoma Study. Genes Chromosome Cancer 2000;27:337-44.
[9]Barr FG. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol 1997;19:483-91.
[10]Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001;20:5736-46.
[11]Anderson J, Gordon A, Pritchard-Jones K, et al. Genes, chromosomes and rhabdomyosarcoma. Genes Chromosome Cancer 1999;26:275-85.
[12]Lohk J,Lehtl K,Westermarck J,etal. Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbo112-myristatel3-acetate[J].Eur J Biolchem,1996,239:239.
[13]Nawrocki B,Polette M,March Met al.Expression of matrix metalloproteinases and their inhibitors in human bonchoput monary carcinoma:quantificative and morphological analyses[J].Int J Cancer,1997,72:556.
[14]Kawano N,Osawa H, Takaaki L,et al.Expression of gelatinase A,tissue inhibitor of metalloproteinase-2, matrily in and trypsin (ogen) in lung neoplasms[J].Human Pathol,1997,28:613.
[15]Kitagawa Y,Kunimi K,Uchibayashi T,et al.Expression of mRNA for MT1,2,3 matrix metalloproteinase in human renal cell carcinoma [J]. J Uro 1,1999,162 (3PT):905-909.
[16]Liano E,Pendas AM,Freije JP,et al.Identification and characterization of human MTS-MMP,a new membrane bound activaor of progelatinase overexpression in brain tumor[J].Cancer Res,1999,59(11):2570-2576.
[17]Fang J, Shing Y, Yan L, et al. Matrix metalloproteinase-2 is required for switch to the angiogenic phenotype in a tumor model [J]. Proc Matl Acad Sci Usa,2000,97 (8):3884-3889.
[18]Weidner N,Folkman J,Pozza F,et al.Tumor angiogenesis:a new significant and independent prognostic indicator in early stage breast carcinoma[J]. Nat Cancer Inst,1992,84(24):1875-87.
[19]Chen JM, Fortunato M, Stevens RA et al (2001) Activation of progelatinase A by mammalian legumain, a recently discovered cysteine proteinase. Biol Chem 382(5):777-783
[20]Liu C, Sun C, Huang H et al (2003) Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res 63(11):2957-2964
[21]Murthy RV, Arbman G, Gao J et al (2005) Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res 11(6):2293-2299
[22]Kroger N, Milde-Langosch K, Riethdorf S et al (2006) Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res 12(1):159-168
[23]Crisi GM, Marconi SA, Makari-Judson G et al (2005) Expression of c-kit in adenoid cystic carcinoma of the breast. Am J Clin Pathol 124(5):733-739
[24]Muehaneta-Kubara EC, el Nahas AM, Myofibroblast phenotypes expression in Experimental renal scarring[J].Nephrol Dial Transplant,1997:12(5):904-910
[25]Noel, A, Munant, C, Nusgens, B, Lapiere, C.M. and Foidart, J.M. Different mechanisms of extracellular matrix remodeling by fibroblasts in response to human mammary neoplastic cells [J].Invasion Metastasis1993:13:72-81.
[26]Nakayama H, Enzan H, Miyazaki E, Toi M, Alpha smooth muscle actin positive Stromal cells in gastric carcinoma[J].Clin Pathol 2002:55:741-744
[27]王立峰,王瑞芬,郝兆星.胃癌中肿瘤相关纤维母细胞蛋白表达改变及意义[J].世界华人消化杂志2007.7,15(20)：2263-2267
[28]Massague J, Chen YC. Controlling TGF-β signaling.Genes Dev.2000; 14:627-644
[29]王华,杨光华,步宏等.转化生长因子β及其受体在横纹肌肉瘤的表达.临床与实验病理学杂志.2002；18：61-64.
[30]Wang Hua, Yang GunagHua, Bu Hong et al.Systematic analysis of the TGF-beta/smad signalling pathway in the rhabdomyosarcoma cell line RD. International journal of experimental phathology.2003;84(3):115-125.
[31]NCI. Cancer incidence and survival among children and adolescents:United States SEER Program 1975-1995. National Cancer Institute.
[32]Jerry A S, Carol L S. Rhabdomyosarcoma:Review for the Ophthalmologist. Survey of Ophthalmology,2003,48 (1):39-57
[33]Jerry A S, Carol L S, Richard S. Survey of 1264 patientswith orbital tumors and simulating lesions. Ophthalmology,2004,111 (5):997-1008
[34]刘复生.中国肿瘤病理学分类(下).北京：科学技术文献出版社,2001：5
[35]Shields CL, Shields JA, Honavar SG, Demirci H:Clinical spectrum of primary ophthalmic rhabdomyosarcoma. Ophthalmology,2001,108:2284-2292
[36]Barnes L.Surgical pathology of the head and neek.In:Tumors and Tumor-like lesions of the sotf tissue. NewYbrk, NY:Marcel Decker,1985:725-880
[37]Crist W, Gehan EA, Ragab AH, et al.The third Intergroup Rhabdomyosarcoma Study. J Clin oncol,1995,13(3):610-630
[38]Koscielniak E, Jurgens H, Winkler K, et al.Treatment of sot ftissue sarcoma in Children and adolescence.A report of the German Copoerative Sotf Tissue Sarcoma Study. Cance r,1992,70(10):2557-2567
[39]Newton WA Jr, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification-an Intergroup Rhabdomyosarcoma Study. Cancer 1995; 76:1073-85.
[40]Loh EWJ, Scrable HJ, Livanos E, et al. Human chromosome 11 contains two different growth supresor genes for embryonal rhabdomyosarcoma. Proc Natl Acad Sci USA 1992;89:1755-9.
[41]Bridge JA, Liu J, Weibolt V, et al. Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization:an Intergroup Rhabdomyosarcoma Study. Genes Chromosome Cancer 2000;27:337-44.
[42]Barr FG. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol 1997;19:483-91.
[43]Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001;20:5736-46.
[44]Anderson J, Gordon A, Pritchard-Jones K, et al. Genes, chromosomes and rhabdomyosarcoma. Genes Chromosome Cancer 1999;26:275-85.
[45]Barrett AJ, Rawlings ND, O'Brien EA The MEROPS database as a protease information system. J Struct Bio 2001:1134(2-3):95-102
[46]Kroger N, Milde-Langosch K, Riethdorf S et al.Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res 2006:12(1):159-168
[47]Crisi GM, Marconi SA, Makari-Judson G et al.Expression of c-kit in adenoid cystic carcinoma of the breast.Am J Clin Pathol 2005:124(5):733-739
[48]Chen JM, Fortunato M, Stevens RA et al) Activation of progelatinase A by mammalian legumain, a recently discovered cysteine proteinase. Biol Chem 2001:382(5):777-783
[49]Liu C, Sun C, Huang H et al.Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res.2003:63(11):2957-2964
[50]Parham DM. Pathologiec classification of rhabdomyosarcomas and correlation With molecular studies.Mod Pathol,2001,14(5):506-514
[51]EL-Badry OM, Minniti C, Kohn EC, et al. Insulin-like growth factor Ⅱ acts as an antocrine growth and motility factor in hmuna rhabdomyosarcoma tumors. Cell Groth Diff.1990; 1:325-331.
[52]Schweigerer L, Neufeld G, Mergia A, et al.Basic fibroblast growth factor In human Rhabdomyosarcoma cells:implications for the proliferation and neovasecularization of myoblast-derived tumors. Proc Natl Aead Sci USA,1987; 84:842-846.
[53]De Giovanni C, Landuzzi L. Frabetti F, et al.Antisense epidermal growth factor receptor transfection impairs the proliferative ability of humna rhabdomyosarcoma cells.Cancer Res.1996:56:3898-3901.
[54]Wang Hua, Yang GunagHua, Bu Hong et al.Systematic analysis of the TGF-beta/smad signalling pathway in the rhabdomyosarcoma cell line RD. International journal of experimental phathology.2003;84(3):115-125.
[55]Massague J, Chen YC. Controlling TGF-β signaling.Genes Dev.2000; 14:627-644
[56]Jeffrey LW, Liliana A, Juan Carcamo, et al. TGF-β signals through a heteromeric protein kinase receptor complex.Cell.1992;71:1003-1014.
[57]Heldin CH, Miyazon Kohei, Ten Dijke P. TGF-β signalling from cell membrane to nucleus through smad protein.Nature.1997;390:465-471
[58]Robert AB, Anzano MA, Wakefield LM, et al.Type beta transforming growth factor:a bifunctional regulator of cellular groth. Proc Natl Acad Sci USA.1985; 82:119-123.
[59]Roberts AB, Anzano MA, Lamb LC, et al. New class of transforming growth factors potentiated by epidermal gorwth factor:isolation from non-neoplastic tissues. Proc. Natl. Acad.Sci.USA.1981;78(9):5339-5343.
[60]Wong SF and Lai LC. The role of TGF beta in human cancers. Pathology 2001; 33:85-92.
[61]Hu XiaoTang, Zhang XiaoHong, et al.Differential effects of transforming growth factor on cell cycle regulatory molecules in human myeloid leukemia cells.Oncogene.2001:20:6840-6850.
[62]Kamaraju AK and Roberts AB.Roel of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-beta-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo.J Biol Chem.2005;14, 280(2):1024-1036.
[63]de Lujan Alvarez M, Ronco MT, Ochoa JE, et al.Interferon alpha-induced apoptosis on rat preneoplastic liver is mediated by hepatocytic transforming gorwth factor beta(1), Hepatology2004:40(2):394-402.
[64]Danforth DN Jr. All trans-retinoic acid acts synergistically wih hydroxytamoxifen and transforming gorwth factor beta to stimulate apoptosis in MCF-7 breast cancer cells. J Endocrinol.2004:183(2):395-404.
[65]Nawshad A, LaGamba D, and Hay ED.Transforming growth factor beta (TGF-β) signaling in palatal growth, apoptosis and epithelial Mesenchymal transformation (EMT). Arch Oral Biol.2004:49(9):675-689.
[66]Blobe GC, SchiemannWP, Lodish HF. Role of transforming growth factor β in human disease. New Eng J Med.2000:342:1350-1358.
[67]Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type Ⅱ TGF-beta receptor in colon cancer cells with micro-satellite instability. Science. 1995;268:1336-1338.
[68]Gorsch SM,Memoli VA,Stukel TA,Gold LI,Arrick BA.Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer.Cancer Res 1992;52:6949-6952
[69]Akhurst RJ.TGF-beta antagonists:why suppress a tumor suppressor? J Clin Invest 2002;109:1533-1536
[70]Tian F, Da Costa Byfield S,Parks WT,et al;Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines.Cancer Res2002;63:8284-8292
[71]Siegel PM,Shu W,Cardiff RD,Muller WJ,Massague J.Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis.Proc Natl Acad Sci USA 2003;100:8430-8435.
[72]Albo D,Berger DH,Tuszynski GP.The effect of thombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.J Surg Res 1998;76:86-90
[73]Farina AR,Coppa A, Tiberio A,et al.Transforming growth factor-beta 1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity.Int J Cancer 1998;75:721-730.
[74]Ohuchida K,Mizumoto K, Murakami M. et al.Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res 2004;64:3215-3222
[75]De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003;200:429-447
[76]Micke P,Ostman A.Tumor-stroma interaction:cancer-associated fibroblasts as novel targets in anti-cancer therapy?Lung Cancer 2004;45 Suppl 2:S163-175
[77]Thiery JP, Chopin D.Epithelial cell plasticity in development and tumor progression.Cancer Metastasis Rev 1999;18:31-42
[78]Zavadil J, Bottinger EP.TGF-beta and epithelial-to-mesenchymal transitions.Oncogene 2005;24:5764-5774
[79]Xu Z,Shen MX,Ma DZ et al. TGF-beta 1 promoted epithelial- to-mesenchymal transformation and cell adhesion contribute to TGF-beta enhanced cell migration in SMMC-7721 cells. Cell Res 2003;13:343-350
[80]Han G, Lu SL, Li AG,et al.Distinct mechanisms of TGF-beta 1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis.J Clin Invest 2005;115:1714-1723
[81]Peinado H,Quintanilla M,Cano A.Transforming growth factor beta-1 induces snail trancription factor in epithelial cell lines:mechanisms for epithelial mesenchymal transitions.J Biol Chem 2003;278:21113-21123
[82]Hasegawa Y,Takanashi S, Kanehira Y,et al.Transforming growth factor-beta 1 level correlates with angiogenesis,tumor progression,and prognosis in patients with nonsmsll cell lung carcinoma.Cancer 2001;91:964-971
[83]Tuxhorn JA, McAlhany SJ, Yang F,et al. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model.Cancer Res 2002;62:6021-6025
[84]Druker BJ, Mamon HJ, Roberts TM. Oncogene, growth factors, and signal transduction. New Engl J Med.1989:321:1383-1391.
[1]NCI. Cancer incidence and survival among children and adolescents:United States SEER Program 1975-1995. National Cancer Institute.
[2]Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-Ⅳ: results for patients with nonmetastatic disease. J ClinOncol,2001,19:3091-102.
[3]Andrea S, Jayant R. Rhabdomyosarcoma India J Pediatr,2004,71(4):331-337.
[4]Weiss SW, Goldblum JR. Rhabdomyosarcoma. In:Weiss SW, Goldblum JR. eds. Enzinger andWeiss's Soft Tissue Tumors. St. Louis,CV Mosby Co. Edition 4,2001, 785-835.
[5]NishiM, Hstae Y. Ep idemiology if malignment neop lasms in soft tissue during childhood j Exp Clin Cancer Res,2004,123 (3):437-440.
[6]Meyer WH, Spunt SL. Soft tissue sarcomas of childhood. Cancer Treat Rev 2004;30:269-80.
[7]Pappo AS, Shapiro DN, Crist WM, Maurer HM. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 1995;13:2123-39.
[8]Ruymann FB, Maddux HR, Ragab A, et al. Congenital anomalies associated with rhabdomyosarcoma:an autopsy study of 115 cases:a report from the Intergroup Rhabdomyosarcoma Study Committee. Med Pediatr Oncol 1988;16:33-9.
[9]Li FP, Fraumeni JR, Mulvihill JT, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988;48:5358-62.
[10]Birch JM, Hartley AL, Blair V, et al. Cancer in the families of children with soft tissue sarcoma. Cancer 1990; 66:2239-48.
[11]Bargonetti J, Manfredi JJ. Multiple roles of tumor suppressor p53. Curr Opin Oncol 2002;14:86-91.
[12]Newton WA Jr, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification- an Intergroup Rhabdomyosarcoma Study. Cancer 1995; 76:1073-85.
[13]Coffin C. The new international rhabdomyosarcoma classification, its progenitors and considerations beyond morphology. Adv Anat Pathol 1997;4:1-16.
[14]Loh EWJ, Scrable HJ, Livanos E, et al. Human chromosome 11 contains two different growth supresor genes for embryonal rhabdomyosarcoma. Proc Natl Acad Sci USA 1992;89:1755-9.
[15]Bridge JA, Liu J, Weibolt V, et al. Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization:an Intergroup Rhabdomyosarcoma Study. Genes Chromosome Cancer 2000;27:337-44.
[16]Barr FG. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol 1997;19:483-91.
[17]Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001;20:5736-46.
[18]Anderson J, Gordon A, Pritchard-Jones K, et al. Genes, chromosomes and rhabdomyosarcoma. Genes Chromosome Cancer 1999;26:275-85.
[19]Jerry A S, Carol L S. Rhabdomyosarcoma:Review for the Ophthalmologist. Survey of Ophthalmology,2003,48 (1):39-57
[20]Jerry A S, Carol L S, Richard S. Survey of 1264 patientswith orbital tumors and simulating lesions. Ophthalmology,2004,111 (5):997-1008
[21]何彦津,宋国祥,丁莹.3476例眼眶占位性病变的组织病理学分类.中华眼 科杂志.2002,38(7)：396-398
[22]刘复生.中国肿瘤病理学分类(下).北京：科学技术文献出版社,2001：5
[23]Shields CL, Shields JA, Honavar SG, Demirci H:Clinical spectrum of p rimary ophthalmic rhabdomyosarcoma. Ophthalmology,2001,108:2284-2292
[24]Herzog, C E, Stewart, JM, Blakely, M L. Pediatric soft tissue sarcomas. Surg Oncol Clin N Am,2003,12:419-420
[25]常彬,李锋,陆天才.横纹肌肉瘤分子遗传学研究进展.临床与实验病理学杂志,2003,19(1)：82-84
[26]Shields JA, Shields CL.Rhabdomyosarcoma review for the ophthalmologist Surv ophthalmol,2003; 48 (1):39-55
[27]Lanzkowsky P.Rhabdomyosarcoma and Other Soft tissue Sarcomas Manual of Pediatric Hematology and Oncology 3re eds. New York Academic Press, 2000:527-553
[28]Raney RB, Anderson JR, Kollath J. Late effects of therapy in 94 patients with localized rhabdomyosarcoma study(IRS-Ⅲ),1984-1991.Med pediatr Oncol, 2000;64(6):413-420
[29]Yip CC,Kersten RC,McCulley TJ,Ballard ET,Kulwin DR. Osteogenic sarcoma after orbital radiation rhabdomyosarcoma. Ophthalmology,2003;110(10):1196-1199
[30]Donaldson SS, Meza J, BrenemanJC, Crist WM, Laurie F, Qualman SJ, Wharam M. Result from the IRS-IV randomized trial of hyperfraction radiotherapy in children with rhabdomyosarcoma-a report from IRSG. Int J Pediat Oncol Biol Phys,2001; 51(3):718-728
[31]Suzanne L. Wolden, Leonard H, Wexler, Dennis H, Kraus, Michael P. Laquaglia, Eric Lis, Paul A. meyears intensify-modulated radiotherapy for head-and neck rhabdomyosarcoma Eur Cancer,2005;61(5):1432-1438
[32]Buwalda J, Schouwenburg PF, Blank LE, Merks JH, Copper MP, Strackee SD,Voute PA, Caron PA, Caron HN.A norel local treatlment strategy for advanced stage head and neck rhabdomyosarcoma in children.results of the AMORE protocol Eur J Cancer,2003;39(11):1594-1602
[33]Hartmann JT, Datel S.Recent developments in salvagechemotherapy for patients with metastatic soft tissue sarcoma. Drugs,2005;62(2):167-178
[34]Casanova M, Ferrari A, BisognoG.Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas:pilot study for the upcoming European Rhabdomyosarcoma Protocol Cancer,2004;101(7):1664-1671
[35]Pappo AS, Lyden E, Breneman J. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma:an intergroup rhabdomyosarcoma study.J Clin Oncol, 2001;19(1):213-219
[36]Sandler E, Lyden E, Ruymann F. Efficacyofifosfamide and doxorubicin given as a phase Ⅱ window in children with newly diagnosed metastatic rhabdomyosarcoma:a report from the Intergroup Rhabdomyosarcoma Study Group. Med pediatr Oncol,2001;37(5):442-448
[37]Breitfeld PP, Lyden E, Raney RB, Teot LA, Wharam M,Lobe T, Crist WM, Maurer HM, Donaldson SS, Ruymann FB. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic hhabdomyosarcoma when administered with irradiation and combination chemotherapy:a report from the Intergroup Rhabdomyosarcoma Study Group. J Peiatr Hematol Oncol,2001; 23(4):225-233
[38], Goto T, Kosaku H, Kobayashi H, Hozumi T, Kondo T. Soft tissue sarcoma:post-operative chemotherapy Gan To Kagaku Ryoho,2004;31 (9):1324-1330
[39]Stevens M, Ray A, Bouvet N, Ellershaw C, Sanchezde Toledo J, Oberlin O. SIOP MMT95 Intensified (6 drug)versus standard (IVA)chemotherapy for high risk nonmetastatic rhabdomyosarcoma(RMS).J Clin Oncol,2004;22(4):8515
[40]Raney RB, Anderson JR, Barr FG. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decade of life:A select review of Intergroup Rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study. J Peiatr Hematol Oncol,2001;23(4):215-220
[41]Weigel BJ, Breitfeld PP, Hawkins D, Crist WM, Baker KS.Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Peiatr Hematol Oncol,2001;23(5):272-276
[42]Veldwijk MR, Berlinghoff S, Hengge UR, Zeller WJ,Wenz F,Fruehauf S. Suicide gene therapy of sarcoma cell lines using recombinant adeno-associated virus vectors. Cancer Gene Ther,2004; 11(8):577-584
[43]Bortoluzzi S, Bisognin A,Tomualdi C, Danieli GA. Novel genes,possibly relevant for molecular diagnosis or therapy of human rhabdomyosarcoma,a detected by genomic expression profiling Gene,2005;348(3):65-71
[44]Tanzarella S, Lionello I, Valentinis B. Rhabdomyosarcoma potential target of MAGE-specific immunotherapieas.Cancer Immuno Immunother,2004; 230 (2):315-318